Gilead gets FDA approval in oncology, Bio-Techne acquires Asuragen, AI for tumor targeting, and Achilles completes $175M IPO.

Charles River acquires Retrogenix, IQVIA fully acquires Q2 Solutions, Agios sells $1.8B in oncology, and Alloy forges a $75M series C. 

I sit down with Dr. Benjamin Schwartz an orthopedic surgeon and digital health expert. We talk digital integration, healthcare cost, and how you can get involved in the space.

Mergers in precision oncology testing, Medtronic breakthrough valve replacement, Gyroscope raises capital for AMD, and small molecule genetic treatments get $240M IPO.

A new MS therapeutic, Fujifilm picks CDMO facility site, consolidation in medical services, and a new oncology startup.

92% reduction in COVID mortality, AVEO gets FDA approval, Takeda acquires Maverick and targets emerging markets, and AgomAb raises $74M Series B for regenerative medicine.

Amgen nabs Five Prime Therapeutics in $1.9B deal, KemPharm ligates their way out of debt with ADHD, three failed COVID19 pipelines, and Colfax follows 2019 merger with corporate split.

I sit down with Dr. Mitrani, the Chief Scientific Officer for Organicell, a clinical stage biopharma company focused on regenerative medicine. Their leading product, Zofin is currently in early clinical trials for the treatment of COVID19. Eventually it may be a therapeutic for long haulers.

PRA acquired by Icon, Johnson & Johnson’s vaccine approved, Oncopeptides’ earns FDA approval, Roivant acquires Silicone Therapeutics, and Merck acquires Pandion.

Eli Lilly bets on RIPK1, Charles River spends $875M on cell and gene therapy, Adjuvant Capital gets who’s who in backing, you can now buy an at-home COVID19 testing kit whenever you want, and Abbott does it again for the 389th time.

Genentech’s next tech, GSK divests to invest, Bristol Myers Squibb checks oncology, Cassava Sciences raises capital, Libtayo gets expanded FDA approval, and Hyperfine turns on hyperdrive.

Two Mercks - three stories, Paraxel gets genomes, Genomes get Money, and 2021 is the year of the upsized public offering.

Biogen gets punted but it’s good, lupus breakthroughs, Senseonics raises capital, and Novavax and Johnson & Johnson… and Janssen.

I sit down with John Reites, founder and CEO of Thread Research to discuss eCOA, decentralized clinical trials past, present, and future, and how you can think about a decentralized approach to your project

Thermo Fisher Scientific spends a billion, Boston Scientific also spends a billion and gets FDA approval, Verve pulls $94 million for CRISPR in humans, and Vera raises $80 million for Berger’s disease

100 million vaccines, EvoQ’s NanoDisk, Merck gets FDA priority, and startups in wearables, startups in diagnostics.

Turning CAR T on and off, Fujifilm’s $2 billion investment, Affinivax raises $226 million, and startups to watch

AstraZeneca and W.H.O., vaccine I-told-you-so’s, Phitonex acquired by ThermoFisher, and Axsome reports success in migraine relief.

Trends in science from investors and immune-oncology to decentralized trials and basic research, we look back on 2020

COVID updates, ERT & Bioclinica merge, Philips acquires BioTelemetry, and augmented reality surgeries.